Internal medicine

Pneumococcal infections

Ceftriaxone

Pneumococcal pneumonia

Streptococcus pneumoniae

Antibiotics

Biology

Microbiology

Serotype

Penicillin

Virology

Pneumococcal conjugate vaccine

Pneumonia

Erythromycin

Antimicrobial

Medicine

Antibiotic resistance

Journal of Infection

Pneumococcal conjugate vaccines (PCVs) have led to substantial declines in vaccine-type pneumococcal disease through direct protection of vaccinated persons as well as indirect protection of unvaccinated persons by reducing nasopharyngeal carriage and transmission.1,2 Despite this success, an estimated 4 million pneumococcal disease cases and 22,000 related deaths occur annually in the United States, with otitis media alone causing 1.5 million cases in 2013.3 These infections are often treated with antibiotics, leading to growing concerns regarding Streptococcus pneumoniae (S.

Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009‒2017